- Home
- KALV vs UIS Comparison
KALV vs UIS Comparison
Compare KALV & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- UIS
- Stock Information
- Founded
- KALV N/A
- UIS 1942
- Country
- KALV United States
- UIS United States
- Employees
- KALV N/A
- UIS N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- UIS EDP Services
- Sector
- KALV Health Care
- UIS Technology
- Exchange
- KALV Nasdaq
- UIS Nasdaq
- Market Cap
- KALV 523.1M
- UIS 474.3M
- IPO Year
- KALV N/A
- UIS N/A
- Fundamental
- Price
- KALV $11.18
- UIS $8.17
- Analyst Decision
- KALV Strong Buy
- UIS
- Analyst Count
- KALV 4
- UIS 0
- Target Price
- KALV $29.00
- UIS N/A
- AVG Volume (30 Days)
- KALV 247.5K
- UIS 851.1K
- Earning Date
- KALV 12-05-2024
- UIS 10-29-2024
- Dividend Yield
- KALV N/A
- UIS N/A
- EPS Growth
- KALV N/A
- UIS N/A
- EPS
- KALV N/A
- UIS N/A
- Revenue
- KALV N/A
- UIS $2,020,600,000.00
- Revenue This Year
- KALV N/A
- UIS $0.18
- Revenue Next Year
- KALV $539.64
- UIS $3.27
- P/E Ratio
- KALV N/A
- UIS N/A
- Revenue Growth
- KALV N/A
- UIS 0.29
- 52 Week Low
- KALV $7.21
- UIS $3.32
- 52 Week High
- KALV $16.88
- UIS $8.28
- Technical
- Relative Strength Index (RSI)
- KALV 46.78
- UIS 69.67
- Support Level
- KALV $10.78
- UIS $5.34
- Resistance Level
- KALV $12.12
- UIS $7.60
- Average True Range (ATR)
- KALV 0.72
- UIS 0.46
- MACD
- KALV -0.07
- UIS 0.18
- Stochastic Oscillator
- KALV 41.20
- UIS 95.83
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About UIS Unisys Corporation New
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides solutions that transform digital workplaces securely and create exceptional end-user experiences. CA&I provides digital platform, applications and infrastructure solutions. ECS provides solutions that harness secure, continuous high-intensity computing and enable digital services through software-defined operating environments.